問卷

TPIDB > Search Result

Search Result

篩選

List

40Cases

2021-04-30 - 2022-07-14

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Terminated3Sites

2021-06-14 - 2022-05-13

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2021-09-01 - 2022-04-12

Phase II/III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Terminated5Sites

2023-01-30 - 2026-05-29

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-09-15 - 2025-10-22

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting2Sites

Terminated3Sites

2023-12-29 - 2027-03-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2024-01-01 - 2025-12-31

Phase IV

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Terminated11Sites

2026-03-01 - 2030-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes
  • Condition/Disease

    Obesity or Overweight 、Type 2 Diabetes Mellitus

  • Test Drug

    注射劑

Participate Sites
8Sites

Not yet recruiting1Sites

2026-03-01 - 2030-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
  • Condition/Disease

    Obesity or Overweight

  • Test Drug

    注射劑

Participate Sites
8Sites

Not yet recruiting1Sites

2026-07-01 - 2029-12-30

Phase III

Not yet recruiting
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (Embold)
  • Condition/Disease

    Weight Management

  • Test Drug

    膜衣錠

Participate Sites
10Sites

Not yet recruiting10Sites

1 2 3 4